全文获取类型
收费全文 | 90928篇 |
免费 | 9504篇 |
国内免费 | 2735篇 |
专业分类
耳鼻咽喉 | 878篇 |
儿科学 | 2077篇 |
妇产科学 | 831篇 |
基础医学 | 5206篇 |
口腔科学 | 1075篇 |
临床医学 | 14259篇 |
内科学 | 14028篇 |
皮肤病学 | 669篇 |
神经病学 | 5147篇 |
特种医学 | 3172篇 |
外国民族医学 | 9篇 |
外科学 | 8040篇 |
综合类 | 16734篇 |
现状与发展 | 4篇 |
一般理论 | 1篇 |
预防医学 | 10355篇 |
眼科学 | 1053篇 |
药学 | 10242篇 |
184篇 | |
中国医学 | 7252篇 |
肿瘤学 | 1951篇 |
出版年
2024年 | 189篇 |
2023年 | 1725篇 |
2022年 | 2823篇 |
2021年 | 4403篇 |
2020年 | 4657篇 |
2019年 | 3668篇 |
2018年 | 3340篇 |
2017年 | 3874篇 |
2016年 | 3971篇 |
2015年 | 3525篇 |
2014年 | 6633篇 |
2013年 | 6769篇 |
2012年 | 5647篇 |
2011年 | 5833篇 |
2010年 | 4716篇 |
2009年 | 4339篇 |
2008年 | 4272篇 |
2007年 | 4497篇 |
2006年 | 3971篇 |
2005年 | 3287篇 |
2004年 | 2709篇 |
2003年 | 2352篇 |
2002年 | 1967篇 |
2001年 | 1831篇 |
2000年 | 1486篇 |
1999年 | 1298篇 |
1998年 | 1007篇 |
1997年 | 900篇 |
1996年 | 792篇 |
1995年 | 849篇 |
1994年 | 763篇 |
1993年 | 584篇 |
1992年 | 643篇 |
1991年 | 502篇 |
1990年 | 426篇 |
1989年 | 368篇 |
1988年 | 355篇 |
1987年 | 321篇 |
1986年 | 267篇 |
1985年 | 284篇 |
1984年 | 270篇 |
1983年 | 160篇 |
1982年 | 187篇 |
1981年 | 127篇 |
1980年 | 113篇 |
1979年 | 107篇 |
1978年 | 113篇 |
1977年 | 60篇 |
1976年 | 60篇 |
1975年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
目的 本实验采用HPLC方法建立来自3个产地15批怀牛膝药材的指纹图谱,并对β-蜕皮甾酮,25R-牛膝甾酮,25S-牛膝甾酮进行含量测定,同时通过化学计量学的方法对15批怀牛膝进行质量评价。方法 选用Waters SunFire C18(150 mm×4.6 mm,5 μm)色谱柱,检测波长280 nm,以乙腈-0.1%甲酸水梯度洗脱,流速为1.0 mL·min-1,柱温25℃,进样量10 μL。以β-蜕皮甾酮峰为参照峰,运用软件《中药色谱指纹图谱相似度评价系统(2012版)》对15批怀牛膝药材进行相似度分析,使用Metabo Analyst 5.0网站进行聚类热图分析,使用SIMCA 14.1软件进行PCA和PLS-DA分析。结果 标定了31个共有指纹峰,指认了3个已知成分,并对其进行含量测定,化学计量学分析结果将15批怀牛膝药材样品分为3类,并且筛选了不同产地间潜在的差异性成分。结论 该方法具有良好的精密度、重复性以及稳定性,可为怀牛膝的质量评价与控制提供科学依据及参考。 相似文献
12.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献13.
目的 研究社区获得性肺炎(community acquired pneumonia,CAP)患儿血清维生素A(vitamin A,VA)水平及与免疫功能的相关性,为肺炎病情评估提供一定参考。方法 以入住新乡医学院第一附属医院PICU的63例重度社区获得性肺炎(severe community acquired pneumonia, SCAP)患儿(SCAP组)、普通儿科病区的30例轻度社区获得性肺炎(mild community acquired pneumonia, MCAP)患儿(MCAP组),以及同期体检的30名健康儿童(对照组)为研究对象,检测其血清中VA和免疫球蛋白(immunoglobulin,Ig)G、IgA、IgM水平,及SCAP组体内T淋巴细胞亚群(总T淋巴细胞、CD4、CD8、CD4/CD8),并对SCAP组体内VA水平及以上指标的相关性进行分析。结果 3组性别和年龄差异无统计学意义;血清中VA的平均含量分别为0.36、0.25和0.19 mg/L,CAP组VA的含量较对照组明显降低,且SCAP组明显低于MCAP组( <0.05)。根据WHO推荐的VA诊断标准,3组VA临床缺乏/亚临床缺乏率分别为10.00%、36.67%和61.90%,差异有统计学意义( <0.05)。CAP组血清中Ig水平较对照组明显降低,且SCAP组明显低于MCAP组( <0.05)。SCAP组血中总T淋巴细胞、CD4、CD8和CD4/CD8的平均水平分别为53.28%、30.26%、20.24%和1.59;分析VA水平与免疫相关指标关系发现VA水平与Ig(IgG、IgA、IgM)水平、总T淋巴细胞、CD4呈正相关,与CD8水平不相关。结论 肺炎患儿血清VA水平与病情严重程度及机体免疫功能相关。 相似文献
14.
15.
《Research in social & administrative pharmacy》2022,18(3):2367-2391
ObjectivesSeveral implementation strategies can reduce potentially inappropriate medication (PIM) prescribing. Although use of PIMs has declined in recent years, it remains prevalent. Various strategies exist to improve the appropriateness of medication use. However, little is known about the processes of these different implementation strategies. This scoping review aims to investigate how the process evaluation of implementation strategies for reducing PIM prescribing in the older population has been studied.MethodsWe searched for process evaluations of implementation strategies for reducing PIM prescribing in PUBMED, SCOPUS and Web of Science published between January 2000 and November 2019 in English. We applied the following inclusion criteria: patients aged ≥65 years, validated PIM criteria, and implementation process evaluated. The review focuses on decision support for health care professionals. We described the findings of the process evaluations, and compared the authors’ concepts of process evaluation of the included publications to those of Proctor et al.( 2010).ResultOf 9131 publications screened, 29 met our inclusion criteria. Different process evaluation conceptualizations were identified. Most process evaluations took place in the initial stages of the process (acceptability, adoption, appropriateness, and feasibility) and sustainability and implementation costs were seldom evaluated. None of the included publications evaluated fidelity.Multifaceted interventions were the most studied implementation strategies. Medication review was more common in acceptability evaluations, multidisciplinary interventions in adoption evaluations, and computerized systems and educational interventions in feasibility evaluations. Process evaluations were studied from the health care professionals’ viewpoint in most of the included publications, but the management viewpoint was missing.DiscussionThe conceptualization of process evaluation in the field of PIM prescribing is indeterminate. There is also a current gap in the knowledge of sustainability and implementation costs. Clarifying the conceptualization of implementation process evaluation is essential in order to effectively translate research knowledge into practice. 相似文献
16.
17.
《Vaccine》2022,40(30):3999-4007
BackgroundA value of vaccination framework for economic evaluation (EE) identified unique value concepts for the broad benefits vaccination provides to individuals, society, healthcare systems and national economies. The objectives of this paper were to work with experts in developed countries to objectively identify three priority concepts to extend current EE.MethodsThe previously developed classification of value concepts in vaccination distinguished 18 concepts, categorised as conventional payer and societal perspective concepts and novel broader societal concepts. Their inclusion in current EE guidelines was assessed. Experts identified eight criteria relevant to decision-making and measurement feasibility, which were weighted and used to score each concept. The relative ranking of concepts by importance and the gaps in guidelines were used to identify three priority concepts on which to focus immediate efforts to extend EE.ResultsThe EE guidelines review highlighted differences across countries and between guidelines and practice. Conventional payer perspective concepts (e.g., individual and societal health gains and medical costs) were generally included, while gaps were evident for conventional societal perspective concepts (e.g., family/caregiver health and economic gains). Few novel broader societal benefits were considered, and only in ad hoc cases. The top-three concepts for near-term consideration: macroeconomic gains (e.g., benefiting the economy, tourism), social equity and ethics (e.g., equal distribution of health outcomes, reduced health/financial equity gaps) and health systems strengthening, resilience and security (e.g., efficiency gains, reduced disruption, increased capacity).ConclusionsGaps, inconsistencies and limited assessment of vaccination value in EE can lead to differences in policy and vaccination access. The three priority concepts identified provide a feasible approach for capturing VoV more broadly in the near-term. Robust methods for measuring and valuing these concepts in future assessments will help strengthen the evidence used to inform decisions, improving access to vaccines that are demonstrably good value for money from society’s point of view. 相似文献
18.
19.
重楼是我国传统的名贵中药,七叶一枝花为历版《中国药典》收载的重楼药材两个基原植物之一,具有清热解毒、消肿止痛、活血化瘀等功效,其主要活性成分为甾体皂苷类物质。由于重楼市场需求量剧增和七叶一枝花成药时间较长,导致大量依靠人工种植。然而,人工种植过程中产地、采收年限和采收月份都会影响七叶一枝花的甾体皂苷含量。本文系统地总结了七叶一枝花中主要活性成分甾体皂苷的种类,以及不同产地、不同生长年限及不同采收月份的七叶一枝花根茎中甾体皂苷含量差异的研究现状,以期为进一步研究七叶一枝花品质差异、野生资源驯化及规范化种植提供参考。 相似文献
20.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献